Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Enterprise Value (2021 - 2026)

Aligos Therapeutics filings provide 6 years of Enterprise Value readings, the most recent being -$77.9 million for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 110.02% to -$77.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$77.9 million, a 110.02% decrease, with the full-year FY2025 number at -$77.9 million, down 110.02% from a year prior.
  • Enterprise Value hit -$77.9 million in Q4 2025 for Aligos Therapeutics, down from -$42.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$24.4 million in Q1 2024 to a low of -$242.2 million in Q3 2021.
  • Median Enterprise Value over the past 5 years was -$110.3 million (2022), compared with a mean of -$121.6 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 76.46% in 2024 and later tumbled 728.98% in 2025.
  • Aligos Therapeutics' Enterprise Value stood at -$187.0 million in 2021, then skyrocketed by 56.44% to -$81.4 million in 2022, then crashed by 66.74% to -$135.8 million in 2023, then surged by 72.68% to -$37.1 million in 2024, then plummeted by 110.02% to -$77.9 million in 2025.
  • The last three reported values for Enterprise Value were -$77.9 million (Q4 2025), -$42.1 million (Q3 2025), and -$123.0 million (Q2 2025) per Business Quant data.